anti-CD69 monoclonal antibody

**Anti-CD69 monoclonal antibody** (anti-CD69 mAb) is a therapeutic antibody targeting the CD69 glycoprotein, a marker of early immune cell activation expressed on T cells, B cells, natural killer (NK) cells, neutrophils, and platelets[5]. The drug is under investigation for its immunomodulatory effects in inflammatory diseases and cancer. In preclinical asthma models, anti-CD69 mAb inhibits airway inflammation and airway hyper-responsiveness (AHR) as effectively as the corticosteroid dexamethasone (DXM), reducing eosinophil infiltration, mucus overproduction, and local IL-5 levels—key drivers of inflammation in allergic asthma[1]. In cancer, targeting CD69 may enhance the differentiation and function of tumor-specific CD8+ T cells in tumor-draining lymph nodes, and anti-CD69 mAb has shown synergistic effectiveness with checkpoint inhibitors such as anti-PD-1 in preclinical melanoma models[2][3]. Preclinical studies in autoimmune and allergic models (e.g., collagen-induced arthritis, food allergy diarrhea) suggest broader potential for inflammatory disease applications[7]. Anti-CD69 mAb does not appear to negatively impact general immune function or health in animal models, supporting a potentially favorable safety profile[2][3]. The mechanism(s) of action are complex and may include: promotion of apoptosis in activated immune cells (T cells, eosinophils), reduction of IL-5 (a Th2 cytokine critical for eosinophil survival), modulation of CD8+ T cell differentiation, and attenuation of TOX transcription factor expression in tumor-specific CD8+ T cells, potentially through NFAT-dependent pathways[1][3]. The clinical development of anti-CD69 mAb, such as the fully human mAb GFC-101, is in preclinical stage for indications like bowel irritable syndrome, rheumatoid arthritis, and respiratory disorders[7].

Other names

AIM antibodyEA-1 antibodyEA1 antibodyEA 1 antibodyMLR-3 antibodyMLR3 antibodyMLR 3 antibodyEarly T-cell activation antigen p60 antibodyVery Early Activation Antigen antibody